Meetings
John’s Top Recurring Meetings
Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers are BEAM’s AMR Conference and GAMRIC (formerly, the ESCMID-ASM conference series). Hope to see you there!
- 11-15 April 2025 (Vienna, Austria): ESCMID Global 2025, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. Go here for details.
- 30 Sep-2 Oct 2025 GAMRIC, the Global AMR Innovators Conference (Washington, DC). Formerly the ESCMID-ASM Joint Conference on Drug Development for AMR, this meeting series is being continued under the joint sponsorship of CARB-X, ESCMID, BEAM, GARDP, LifeArc, WHO, and AMR.Solutions. You can’t yet register for the 2025 meeting but please mark your calendar now. The ongoing series is expected to continue that successful format of prior meetings with a (mostly) single-track meeting. You can go here to see details of the outstanding 2024 meeting.
- 19-22 Oct 2025 (Georgia, USA): IDWeek 2025, the annual meeting of the Infectious Diseases Society of America. Details pending; go here for the general meeting website.
- 3-4 Mar 2026 (Basel, Switzerland): The 10th AMR Conference. Sponsored by the BEAM Alliance, the 9th AMR Conference has just concluded and it’s again been an excellent meeting! Please mark your calendar for next year. You can’t register yet, but details will appear here!
Upcoming meetings of interest to the AMR community:
- 28 Mar 2025 (virtual, 10.00-11.15a ET): GARDP webinar entitled “Cefiderocol access project: Where are we now?”. This will be an update on GARDP’s work to enable access via lower-cost manufacturing in India (see the 25 Sep 2023 newsletter for background). Go here to register!
- 3 Apr 2025 (virtual, 10.00-11.15a ET): GARDP webinar entitled “Charting new frontiers in artificial intelligence for antibiotic design.” This is a fascinating area … as background, you might enjoy reading our 5-part series on AI-based discovery that began on 21 Feb 2020. Go here to register!
- 11-15 April 2025 (Vienna, Austria): ESCMID Global 2025, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. See Recurring Meetings list, above.
- During ESCMID, mark your calendar for the Science Policy forum during which we’ll have follow-up from UNGA 2024 (11 April, 3-8p CEST) and Pipeline Monday (14 April) during which we’ll have a variety of sessions on the antimicrobial pipeline. See also the 13 Feb 2025 newsletter for details and commentary.
- I’ve also learned of a 14 April (12.15-1.15p, Hall 8) symposium on mechanisms to expand access to antibiotics. To find this one, you have to go the general program and navigate to Hall 8 at 12.15p. Awkward, but a direct link is not possible due the design of the ESCMID webpage.
- 30 Apr 2025 (virtual, 10-5.15p ET): Presented by Sepsis Alliance, the Sepsis Alliance AMR Conference is 1-day virtual discussion of AMR- and sepsis-focused diagnostics, therapeutics, and advocacy. Go here for details and to register.
- 30 June – 1 July (in person and virtual, Grand Hyatt, Washington DC): BARDA Industry Days 2025 (BID2025) with the theme “Enhancing Health Security With a Sustainable Future.” This is a major annual opportunity to interact with BARDA and ASPR teams and thereby identify potential areas of collaboration in the field of MCM (medical countermeasure) research and development. Go here for details.
- 19-22 Oct 2025 (Georgia, USA): IDWeek 2025, the annual meeting of the Infectious Diseases Society
- 11-15 April 2025 (Vienna, Austria): ESCMID Global 2025. See list of Top Recurring meetings, above.
- 30 June-1 July 2025 (virtual and in Washington, DC): BID2025: BARDA Industry Days — Enhancing Health Security With a Sustainable Future. BID provides the opportunity to discuss U.S. government medical countermeasure (MCM) priorities, provide the private sector an informal opportunity to interact with BARDA and ASPR teams, and identify potential areas of collaboration in the field of MCM research and development. Go here for details.
- 30 Sep-2 Oct 2025 GAMRIC, the Global AMR Innovators Conference (Washington, DC; formerly the ESCMID-ASM Joint Conference on Drug Development for AMR). See list of Top Recurring meetings, above..
- 19-22 Oct 2025 (Georgia, USA): IDWeek 2025. See list of Top Recurring meetings, above.
- 11-19 Oct 2025 (Annecy, France, residential in-person program): ICARe (Interdisciplinary Course on Antibiotics and Resistance) … and 2025 will be the 9th year for this program. Patrice Courvalin orchestrates content with the support of an all-star scientific committee and faculty. The resulting soup-to-nuts training covers all aspects of antimicrobials, is very intense, and routinely gets rave reviews! Seating is limited, so mark your calendars now if you are interested. Applications should open ~March 2025 — go here for more details.
- 3-4 Mar 2026 (Basel, Switzerland): The 10th AMR Conference sponsored by the BEAM Alliance. See list of Top Recurring meetings, above.
- [NEW] 8-13 Mar 2026 (Renaissance Tuscany Il Ciocco, Italy): 2026 Gordon Research Conference (GRC) entitled “Antibacterials of Tomorrow to Combat the Global Threat of Antimicrobial Resistance.” A Gordon Research Seminar (GRS) will be held the weekend before (7-8 Mar) for young doctoral and post-doctoral researchers. Space for the GRS and the GRC is limited; for details and to apply, go here for the GRC and here for the GRS.
- OpenWHO: “Antimicrobial Resistance in the environment: key concepts and interventions.” Per the webpage for the course, it will teach you “…why addressing AMR in the environment is essential and gain insights into how action can be taken to prevent and control AMR in the environment at the national level.” This course builds on WHO’s 2024 Guidance on wastewater and solid waste management for manufacturing of antibiotics. For further reading, see also the 25 Sep 2023 newsletter entitled “Manufacturing underpins both access and stewardship: Cefiderocol as a case study” and the 28 Jan 2024 newsletter entitled “EMA Concept Paper: Guidance on manufacturing of phage products”.
- [NEW] GARDP’s REVIVE website provides an encyclopedia covering a range of R&D terms, recordings of prior GARDP webinars, a variety of viewpoint articles, and more! Check it out!
- [NEW] Similarly, the CARB-X website provides a range of recordings from webinars, bootcamps, and more. A bit of browsing would be time well spent!
Share
Now live: HERA’s call for rapid point-of-care susceptibility devices
Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The call is now live! Title: Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical Device (HADEA/2025/CPN/0006) Funding and Tenders portal link: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/2e5c607e-6e55-4268-b99a-730c5db350b7-CN “This call for tenders aims to speed up the development of an in
Updates: CARB-X TPPs; Independent Panel for Evidence for Action against AMR
Dear All, Two quick updates this evening. First, you will recall that CARB-X have announced their initial 2025 funding round (26 Feb 2025 newsletter), with a call for applications for funding of work on (i) small molecules for Gram-negative infection and (ii) diagnostics for typhoid. In support of these calls, TPPs (target product profiles) for both
Unexpected resistance: The tale of rifaximin and daptomycin
Dear All (and with thanks to Patricia Bradford for taking the lead on this newsletter): Today, this paper in Nature takes us on a trip to the land of unintended consequences: Turner, A.M., Li, L., Monk, I.R. et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature 635, 969–977 (2024). https://doi.org/10.1038/s41586-024-08095-4. A wonkish summary is found below
CARB-X announces its 2025 funding round
Dear All, At BEAM’s AMR Conference in Basel, Team CARB-X have today announced their 2025 funding round. Key points: Two themes: (i) Direct-acting small molecule therapeutics for Gram-negatives (same as in 2024) and (ii) diagnostics for typhoid fever in low-resource settings. 23 Mar 2025 newsletter update: The TPPs for both themes have been released: Small